Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Krenitsky Pharmaceuticals Inc.

Latest From Krenitsky Pharmaceuticals Inc.

CeNeRx secures $9 million in private financing

CeNeRx BioPharma, a US private biopharmaceutical company, has secured $9 million from existing investors and financial institutions.

Neurology Companies

CeNeRx BioPharma Inc.

CeNeRx BioPharma in-licenses and develops existing drugs not sold in the US, but shown effective for treating CNS disorders. With the acquisition of a well-characterized class of compounds known as reversible inhibitors of monoamine oxidase, CeNeRx aims to bring the first reversible broad-spectrum antidepressant to the US market.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Krenitsky Pharmaceuticals Inc.
  • Senior Management
  • Thomas A Krenitsky, PhD, Pres. & CEO
    Wayne R Eberhardt, VP, Bus. Dev. & Gen. Counsel
  • Contact Info
  • Krenitsky Pharmaceuticals Inc.
    Phone: (919) 493-4631
    Four University Place
    4611 University
    Durham, NC 27707